Neurohumoral Mechanisms in Rheumatoid Arthritis

References

• Perretti M, Mugridge K G, Becherucci C, Parente L. Evidence that interleukin-1 and lipoxygenase metabolites mediate the lethal effect of complete Freund's adjuvant in adrenalectomized rats. Lymphokine Cytokine Res 1991; 10: 239–43
   PubMedGoogle Scholar
• Berczi I, Nagy E. Neurohormonal control of cytokines during injury. Brain control of the response to injury, NJ Rothwell, F Berkenbosch. Cambridge University Press, New York 1994
   Google Scholar
• Chikanza I C, Petrou P, Kingsley G, Chrousos G P, Panayi GS. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281–8
   PubMed Web of Science ®Google Scholar
• Baerwald C GO, Panayi G, Lanchbury S. JS. A new Xmnl polymorphism in the regulatory region of the corticotropin releasing hormone gene. Hum Genet 1996; 97: 697–8
   PubMedGoogle Scholar
• Baerwald C GO, Panayi G S, Lanchbury JS. Three novel polymorphisms in the regulatory region of the corticotropin releasing hormone (CRH) gene in patients with rheumatoid arthritis and controls. Br J Rheumatol 1996; 35: 107, Abstr.
   Google Scholar
• Grossman A, Gaillard R C, McCarthney P., Rees L H, Besser GM. Opiate modulation of the pituitary-adrenal axis: effect of stress and circadian rhythm. Clin Endocrinol 1982; 17: 279–86
   PubMedGoogle Scholar
• Kassimos D, Choy E H, Grossmann A B, Chikanza I C, Panayi GS. Endogenous opioid tone in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35: 436–40
   PubMedGoogle Scholar
• Chikanza I C, Panayi GS. Hypothalamic-pituitary mediated modulation of immune function: prolactin as a neuroimmune peptide. Br J Rheumatol 1991; 30: 203–7
   PubMedGoogle Scholar
• Reber PM. Prolactin and immunomodulation. Am J Med 1993; 95: 637–44
   PubMed Web of Science ®Google Scholar
• Dougados M, Duchesne L, Armor B. Bromocriptine and cyclosporine A combination therapy for rheumatoid arthritis. Arthritis Rheum 1988; 31: 1333
   PubMedGoogle Scholar
• Thompson M, Bywaters E GL. Unilateral arthritis following hemiplegia. Ann Rheum Dis 1962; 21: 370–7
   PubMed Web of Science ®Google Scholar
• Felten D L, Felten S Y, Bellinger D, Lorton L. D. Noradrenergic and peptidergic innervation of secondary lymphoid organs: role in experimental arthritis. Eur J Clin Invest 1992; 22: 37–41, Suppl 1
   PubMedGoogle Scholar
• Wiegmann K, Muthyala S, Kim D H, Amason B G, Chelmicka-Schorr E. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J Neuroimmunol 1995; 56: 201–206
   PubMedGoogle Scholar
• Felten S Y, Felten D L, Bellinger D L, Olschowska JA. Noradrenergic and peptidergic innervation of lymphoid organs. Chem Immunol 1992; 52: 25–48
   PubMedGoogle Scholar
• Felten S Y, Olschowska JA. Noradrenergic sympathetic innervation of the spleen: II. Tyrosine hydroxylase (TH)-positive nerve terminals form synaptic-like contacts on lymphocytes in the spleen white pulp. J Neurosci Res 1987; 18: 37–48
   PubMed Web of Science ®Google Scholar
• Baerwald C, Graefe C, von Wichert P, Krause A. Decreased density of β-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatoid arthritis. J. Rheumatol 1992; 19: 204–10
   PubMedGoogle Scholar
• Krause A, Steitz A, von Wichert P, Baerwald C. Influence of cytokines on the density of β2-adrenergic receptors on peripheral blood mononuclear cells in vitro. Cytokine 1995; 7: 273–6
   PubMedGoogle Scholar
• Mapp P I, Blake D R. Neuropeptides and the synovium. In: editor? Mechanisms and models in rheumatoid arthritis. London 1995; 317–32, Academic Press
   Google Scholar
• Savino W, Dardenne M. Immune-neuroendocrine interactions. Immunol Today 1995; 16: 318–22
   PubMedGoogle Scholar
• Levine J D, Clarke R, Devor M, Helms C, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984; 226: 547–9
   PubMed Web of Science ®Google Scholar
• Sternberg E M, Young W S, III, Bernardini R, et al. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989; 86: 4771–5
   PubMed Web of Science ®Google Scholar
• Gough A, Sheeran T, Arthur V, Panayi G, Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. Scand J. Rheumatol 1994; 23: 46–8
   PubMed Web of Science ®Google Scholar
• Podgorski M R, Goulding N J, Hall N D, Flower R J, Maddison PJ. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis. J. Rheumatol 1992; 19: 1668–71
   PubMedGoogle Scholar
• Auphan N, Di Donato J A, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270: 286–90
   PubMed Web of Science ®Google Scholar
• Choy E H, Kingsley GH., Corkill M M, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chryso-therapy. Br J. Rheumatol 1993; 32: 734–9
   PubMedGoogle Scholar
• Harris E DJ, Emkey R D, Nichols J E, Newberg A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10: 713–21
   PubMed Web of Science ®Google Scholar
• Kirwan J R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J. Med 1995; 333: 142–6
   PubMed Web of Science ®Google Scholar